200 related articles for article (PubMed ID: 21911022)
1. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice.
Camacho AI; de Souza J; Sánchez-Gómez S; Pardo-Ros M; Irache JM; Gamazo C
Vaccine; 2011 Oct; 29(46):8222-9. PubMed ID: 21911022
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice.
Camacho AI; Irache JM; de Souza J; Sánchez-Gómez S; Gamazo C
Vaccine; 2013 Jul; 31(32):3288-94. PubMed ID: 23727423
[TBL] [Abstract][Full Text] [Related]
3. Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies.
Camacho AI; Souza-Rebouças J; Irache JM; Gamazo C
Methods; 2013 May; 60(3):264-8. PubMed ID: 23046911
[TBL] [Abstract][Full Text] [Related]
4. Outer Membrane Vesicles Derived from
Tian H; Li B; Xu T; Yu H; Chen J; Yu H; Li S; Zeng L; Huang X; Liu Q
Appl Environ Microbiol; 2021 Sep; 87(19):e0096821. PubMed ID: 34319809
[TBL] [Abstract][Full Text] [Related]
5. Effective protection of mice against Shigella flexneri with a new self-adjuvant multicomponent vaccine.
Pastor Y; Camacho A; Gil AG; Ramos R; Ceráin AL; Peñuelas I; Irache JM; Gamazo C
J Med Microbiol; 2017 Jul; 66(7):946-958. PubMed ID: 28721849
[TBL] [Abstract][Full Text] [Related]
6. Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice.
Mitra S; Barman S; Nag D; Sinha R; Saha DR; Koley H
FEMS Immunol Med Microbiol; 2012 Nov; 66(2):240-50. PubMed ID: 22762732
[TBL] [Abstract][Full Text] [Related]
7. Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.
Kim JO; Rho S; Kim SH; Kim H; Song HJ; Kim EJ; Kim RY; Kim EH; Sinha A; Dey A; Yang JS; Song MK; Nandy RK; Czerkinsky C; Kim DW
Clin Vaccine Immunol; 2015 Apr; 22(4):381-8. PubMed ID: 25651919
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
[TBL] [Abstract][Full Text] [Related]
9. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis.
Mitra S; Chakrabarti MK; Koley H
Vaccine; 2013 Jun; 31(31):3163-73. PubMed ID: 23684822
[TBL] [Abstract][Full Text] [Related]
10. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
Jennison AV; Roberts F; Verma NK
FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
[TBL] [Abstract][Full Text] [Related]
11. Vaccination With Mouse Dendritic Cells Loaded With an IpaD-IpaB Fusion Provides Protection Against Shigellosis.
Arizmendi O; Kumar P; Zheng Q; Stewart JP; Picking WD; Picking W; Martinez-Becerra FJ
Front Immunol; 2019; 10():192. PubMed ID: 30800131
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
Tribble D; Kaminski R; Cantrell J; Nelson M; Porter C; Baqar S; Williams C; Arora R; Saunders J; Ananthakrishnan M; Sanders J; Zaucha G; Turbyfill R; Oaks E
Vaccine; 2010 Aug; 28(37):6076-85. PubMed ID: 20619378
[TBL] [Abstract][Full Text] [Related]
13. Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response.
Mukhopadhaya A; Mahalanabis D; Chakrabarti MK
Vaccine; 2006 Aug; 24(33-34):6028-36. PubMed ID: 16765491
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
[TBL] [Abstract][Full Text] [Related]
16. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.
Heine SJ; Diaz-McNair J; Andar AU; Drachenberg CB; van de Verg L; Walker R; Picking WL; Pasetti MF
J Immunol; 2014 Feb; 192(4):1630-40. PubMed ID: 24453241
[TBL] [Abstract][Full Text] [Related]
17. Vaccine potential for inactivated shigellae.
Osorio M; Bray MD; Walker RI
Vaccine; 2007 Feb; 25(9):1581-92. PubMed ID: 17178431
[TBL] [Abstract][Full Text] [Related]
18. A tetravalent Shigella outer membrane vesicles based candidate vaccine offered cross-protection against all the serogroups of Shigella in adult mice.
Bhaumik U; Halder P; Howlader DR; Banerjee S; Maiti S; Dutta S; Koley H
Microbes Infect; 2023 Jun; 25(5):105100. PubMed ID: 36696935
[TBL] [Abstract][Full Text] [Related]
19. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
Yagnik B; Sharma D; Padh H; Desai P
Vaccine; 2019 May; 37(23):3097-3105. PubMed ID: 31047673
[TBL] [Abstract][Full Text] [Related]
20.
Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
[No Abstract] [Full Text] [Related]
[Next] [New Search]
